Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Niels De Vries"'
Autor:
Changpei Gan, Jing Wang, Alejandra Martínez-Chávez, Michel Hillebrand, Niels de Vries, Joke Beukers, Els Wagenaar, Yaogeng Wang, Maria C. Lebre, Hilde Rosing, Sjoerd Klarenbeek, Rahmen Bin Ali, Colin Pritchard, Ivo Huijbers, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 2, Pp 618-631 (2023)
The mammalian carboxylesterase 1 (Ces1/CES1) family comprises several enzymes that hydrolyze many xenobiotic chemicals and endogenous lipids. To investigate the pharmacological and physiological roles of Ces1/CES1, we generated Ces1 cluster knockout
Externí odkaz:
https://doaj.org/article/87e193186c58427c9b561d417264b90f
Autor:
Changpei Gan, Jing Wang, Yaogeng Wang, Alejandra Martínez-Chávez, Michel Hillebrand, Niels de Vries, Joke Beukers, Maria C. Lebre, Els Wagenaar, Hilde Rosing, Sjoerd Klarenbeek, Onno B. Bleijerveld, Ji-Ying Song, Maarten Altelaar, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 164, Iss , Pp 114956- (2023)
Mammalian carboxylesterase 1 enzymes can hydrolyze many xenobiotic chemicals and endogenous lipids. We here identified and characterized a mouse strain (FVB/NKI) in which three of the eight Ces1 genes were spontaneously deleted, removing Ces1c and Ce
Externí odkaz:
https://doaj.org/article/6feb859d901d4d4c97531a2a7f1a6338
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
Autor:
Imke H. Bartelink, Brendan Prideaux, Gregor Krings, Lisa Wilmes, Pei Rong Evelyn Lee, Pan Bo, Byron Hann, Jean-Philippe Coppé, Diane Heditsian, Lamorna Swigart-Brown, Ella F. Jones, Sergey Magnitsky, Ron J Keizer, Niels de Vries, Hilde Rosing, Nela Pawlowska, Scott Thomas, Mallika Dhawan, Rahul Aggarwal, Pamela N. Munster, Laura J. Esserman, Weiming Ruan, Alan H. B. Wu, Douglas Yee, Véronique Dartois, Radojka M. Savic, Denise M. Wolf, Laura van ’t Veer
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-17 (2017)
Abstract Background Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some
Externí odkaz:
https://doaj.org/article/36493b79564d44c2b1b8ca3d6cd7f195
Autor:
Hilde Rosing, Stijn L.W. Koolen, Laura Molenaar-Kuijsten, Annelie J E Vulink, Niels de Vries, Ron H.J. Mathijssen, Stefanie L. Groenland, Marloes G J van Dongen, Alwin D. R. Huitema, C. Louwrens Braal, Neeltje Steeghs, Jos H. Beijnen
Publikováno v:
Clinical Pharmacology and Therapeutics, 111(2), 477-484. Wiley-Blackwell
Palbociclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 used in the treatment of locally advanced and metastatic breast cancer, and is extensively metabolized by cytochrome P450 enzyme 3A4 (CYP3A4). A pharmacokinetic/pharmacodynamic rela
Autor:
Craig M. Polley, Johannes Aprojanz, Alexei Zakharov, Thiagarajan Balasubramanian, Markus Gruschwitz, Thi Thuy Nhung Nguyen, Hrag Karakachian, Cornelis F.J. Flipse, Ulrich Starke, Christoph Tegenkamp, Niels de Vries
Publikováno v:
Nano Letters, 21(7), 2876-2882. American Chemical Society
Protected and spin-polarized transport channels are the hallmark of topological insulators, coming along with an intrinsic strong spin-orbit coupling. Here we identified such corresponding chiral states in epitaxially grown zigzag graphene nanoribbon
Autor:
Jacobus A. Burgers, Hilde Rosing, Stefanie L. Groenland, Niels de Vries, Dieuwertje R. Geel, Egbert F. Smit, Julie M Janssen, Neeltje Steeghs, Alwin D. R. Huitema, Jos H. Beijnen
Publikováno v:
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics, 109(2), 394-402. WILEY
Clinical Pharmacology and Therapeutics, 109(2), 394-402. WILEY
Crizotinib and alectinib are anaplastic lymphoma kinase (ALK)-inhibitors indicated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). At the currently used fixed doses, interindividual variability in exposure is high. Th
Autor:
Jonathan Emanuel Knikman, Niels de Vries, Hilde Rosing, Annemieke Cats, Henk-Jan Guchelaar, Jos H. Beijnen
Publikováno v:
SSRN Electronic Journal.
Autor:
Michel Brink, Niels de Vries, Vincent Gouttebarge, Maarten van Smeden, Frank J. G. Backx, Edwin A Goedhart, Bionka M. A. Huisstede, Peter Alexander van de Hoef
Publikováno v:
Scandinavian Journal of Medicine & Science in Sports
Scandinavian Journal of Medicine and Science in Sports, 29(4), 515-523. WILEY
Scandinavian Journal of Medicine & Science in Sports, 29(4), 515-523. Wiley
Scandinavian Journal of Medicine and Science in Sports, 29(4), 515. Blackwell Munksgaard
Scandinavian journal of medicine & science in sports, 29(4), 515-523. Blackwell Munksgaard
Scandinavian Journal of Medicine and Science in Sports, 29(4), 515-523. WILEY
Scandinavian Journal of Medicine & Science in Sports, 29(4), 515-523. Wiley
Scandinavian Journal of Medicine and Science in Sports, 29(4), 515. Blackwell Munksgaard
Scandinavian journal of medicine & science in sports, 29(4), 515-523. Blackwell Munksgaard
BACKGROUND: Although the Nordic Hamstring Exercise (NHE) prevents hamstring injury in soccer players effectively, the annual incidence of these injuries still increases. This may be because of poor long-term compliance with the program. Furthermore,
Autor:
Niels de Vries, Marco Spruit
Publikováno v:
Research and Innovation Forum 2020 ISBN: 9783030620653
RIIFORUM
RIIFORUM
Healthcare is a data intensive industry in which data mining has a great potential for improving the wellbeing of patients. However, a multitude of barriers impedes the application of machine learning. This work focuses on medical adverse event predi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0c31f94065feacd45d909ed5c5066d6
https://doi.org/10.1007/978-3-030-62066-0_39
https://doi.org/10.1007/978-3-030-62066-0_39
Autor:
Alwin D. R. Huitema, Stefanie L. Groenland, Jos H. Beijnen, Niels de Vries, Bas Thijssen, Hilde Rosing, Ruben A G van Eerden, Stijn L.W. Koolen, Remy B. Verheijen, Ron H.J. Mathijssen, Neeltje Steeghs
Publikováno v:
Clinical Pharmacokinetics, 59(7), 941-948. Adis
Clinical Pharmacokinetics, 59(7), 941. Adis International Ltd
Clinical Pharmacokinetics, 59(7), 941. Adis International Ltd
Background and Objective: Pazopanib is an oral tyrosine kinase inhibitor used in the treatment of renal cell carcinoma and soft-tissue sarcoma. At the approved dose of 800 mg once daily (QD), 16–20% of patients are being underdosed and at risk of d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8523041abf904f0a19949668d37b9b9e
https://pure.eur.nl/en/publications/31c7fb36-4788-426f-8676-2c471695966c
https://pure.eur.nl/en/publications/31c7fb36-4788-426f-8676-2c471695966c